GlycoMimetics Added To NASDAQ Biotechnology Index
The NASDAQ Biotechnology Index contains securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals, which also meet other eligibility criteria. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology.
For more information about the NBI, please see https://indexes.nasdaqomx.com/Index/Overview/NBI.
About
GlycoMimetics is a clinical-stage biotechnology company focused on the
discovery and development of novel glycomimetic drugs to address unmet
medical needs resulting from diseases in which carbohydrate biology
plays a key role.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171215005277/en/
Source:
GlycoMimetics, Inc.
Investor Contact:
Shari Annes, 650-888-0902
sannes@annesassociates.com
or
Media
Contact:
Jamie Lacey-Moreira, 410-299-3310
jamielacey@presscommpr.com